Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | Filing |
| 2024-03-13 1:32 pm Purchase | 13G | EVOKE PHARMA INC EVOK | LYTTON LAURENCE W | 859,322 9.99% | 859,322 (New Position) | View |
| 2024-03-11 6:39 pm Purchase | 13G | EVOKE PHARMA INC EVOK | Bleichroeder LP | 849,367 9.99% | 849,367 (New Position) | View |
| 2024-02-20 4:38 pm Purchase | 13G | EVOKE PHARMA INC EVOK | Altium Capital Management LP | 1,838,235 9.7% | 1,838,235 (New Position) | View |
| 2024-02-13 06:34 am Purchase | 13G | EVOKE PHARMA INC EVOK | HIRSCHMAN ORIN | 847,000 9.99% | 847,000 (New Position) | View |
| 2021-05-06 4:20 pm Purchase | 13G | EVOKE PHARMA INC EVOK | HIRSCHMAN ORIN | 1,701,185 5.3% | 268,072 (+18.71%) | View |
| 2021-03-25 6:28 pm Sale | 13G | EVOKE PHARMA INC EVOK | HIRSCHMAN ORIN | 1,433,113 4.4% | -266,887 (-15.70%) | View |
| 2021-01-20 07:20 am Purchase | 13G | EVOKE PHARMA INC EVOK | HIRSCHMAN ORIN | 1,700,000 5.3% | 1,700,000 (New Position) | View |
| 2020-02-11 12:05 pm Sale | 13G | EVOKE PHARMA INC EVOK | SPHERA FUNDS MANAGEMENT LTD. | 0 0% | -1,410,946 (Position Closed) | View |